Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C8VF
|
|||
| Drug Name |
Galcanezumab
|
|||
| Synonyms |
Galcanezumab [USAN:INN]; UNII-55KHL3P693; 55KHL3P693
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hyperprolactinaemia [ICD-11: 5A60.1; ICD-10: E22.1; ICD-9: 253.1, 346] | Approved | [1] | |
| Company |
Eli Lilly
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcitonin gene-related peptide receptor (CGRPR) | Target Info | Modulator | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Vascular smooth muscle contraction | ||||
| Reactome | G alpha (s) signalling events | |||
| Calcitonin-like ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.